Philip NUNN,Bret BERNER,Mohammad Reza MASJEDIZADEH
申请号：
US15539094
公开号：
US20180015088A1
申请日:
2015.12.23
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Disclosed herein are formulations and methods of site specific administration of Compound (I) or a pharmaceutically acceptable salt thereof. Compound (I) is a potent BTK inhibitor and hence can be useful for the treatment of diseases such as cancer, autoimmune, and inflammatory diseases.
